CRA Financial Services LLC Sells 37 Shares of Eli Lilly and Company (NYSE:LLY)

CRA Financial Services LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 4,214 shares of the company’s stock after selling 37 shares during the period. CRA Financial Services LLC’s holdings in Eli Lilly and Company were worth $1,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Fairfield Bush & CO. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $107,000. Roundview Capital LLC boosted its stake in shares of Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after purchasing an additional 53 shares in the last quarter. Merit Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $210,000. NewEdge Advisors LLC boosted its stake in shares of Eli Lilly and Company by 9.9% in the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after purchasing an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at $561,000. Institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Trading Down 2.7 %

Shares of LLY stock traded down $15.95 on Friday, reaching $575.66. The company had a trading volume of 5,941,215 shares, compared to its average volume of 3,039,255. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. The stock has a market cap of $546.47 billion, a PE ratio of 80.06, a PEG ratio of 2.47 and a beta of 0.32. The company has a 50-day moving average of $512.56 and a 200-day moving average of $438.41. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.84.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. During the same period in the prior year, the business posted $1.25 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 62.87%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,156 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the sale, the insider now directly owns 101,387,286 shares in the company, valued at approximately $46,037,938,826.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the sale, the chief accounting officer now directly owns 5,378 shares in the company, valued at $2,939,130.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total transaction of $15,509,556.48. Following the completion of the sale, the insider now owns 101,387,286 shares in the company, valued at $46,037,938,826.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,010,309 shares of company stock worth $21,095,701,670. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. Truist Financial upped their price target on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Argus upped their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $532.78.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.